Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies Meeting Abstract
| Authors: | Soumerai, J. D.; Jagadeesh, D.; Salman, H. S.; Lossos, I. S.; Asch, A. S.; Reddy, N.; Kenkre, V. P.; Pagel, J. M.; Persky, D. O.; Awan, F. T.; Magid Diefenbach, C. S.; Huang, W.; Llorin-Sangalang, J.; Gorbatchevsky, I.; Zelenetz, A. D. |
| Abstract Title: | Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120604150 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.7553 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 7553 -- Source: Wos |
